Douglas Pharmaceuticals is pleased to announce the appointment of Henry Jackson as Group General Manager Technical Services following an international executive search conducted by SEQEL Partners.

Douglas Pharmaceuticals is a New Zealand success story with a reputation for innovative research and product development, high manufacturing standards, quality products and outstanding customer service. The business is going through a period of considerable innovation and international growth, resulting in the need to appoint this new position. Reporting to the Chief Operating Officer, Rod De Spong, and working closely with the Chief Scientific Officer, Dr Peter Surman, the GGM Technical Services is a specialist position, acting as a conduit across Research & Development, Operations/Manufacturing and Commercial Functions.

Currently based in Porto Rico, Henry Jackson brings highly relevant experience and capability through a distinguished career with Mylan, Medtronic, Legacy Pharmaceuticals, Valeant Pharmaceuticals and Abbott. Henry is a Post-Doctoral Fellow from Ben May Research Institute, a PhD in Organic Medicinal Chemistry from the University of Iowa, and a Masters of Science in Organic Chemistry from the University of Puerto Rico.

With the global challenges presented by Covid-19, Henry will commence in the position whilst based in Porto Rico, before relocating to Auckland at the appropriate time.

Henry joins Douglas Pharmaceuticals in April 2020.